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Abstract
Motivation: Individual microarray studies searching for prognostic biomarkers often have few samples and low statistical 
power; however, publicly accessible data sets make it possible to combine data across studies.
Method: We present a novel approach for combining microarray data across institutions and platforms. We introduce a new 
algorithm, robust greedy feature selection (RGFS), to select predictive genes.
Results: We combined two prostate cancer microarray data sets, conﬁ  rmed the appropriateness of the approach with the 
Kolmogorov-Smirnov goodness-of-ﬁ  t test, and built several predictive models. The best logistic regression model with 
stepwise forward selection used 7 genes and had a misclassiﬁ  cation rate of 31%. Models that combined LDA with different 
feature selection algorithms had misclassiﬁ  cation rates between 19% and 33%, and the sets of genes in the models varied 
substantially during cross-validation. When we combined RGFS with LDA, the best model used two genes and had a 
misclassiﬁ  cation rate of 15%.
Availability: Affymetrix U95Av2 array data are available at http://www.broad.mit.edu/cgi-bin/cancer/datasets.cgi. The 
cDNA microarray data are available through the Stanford Microarray Database (http://cmgm.stanford.edu/pbrown/). GeneLink 
software is freely available at http://bioinformatics.mdanderson.org/GeneLink/. DNA-Chip Analyzer software is publicly 
available at http://biosun1.harvard.edu/complab/dchip/.
Keywords: combining data, cross-validation, feature selection, microarray expression proﬁ  ling, predictive model, prostrate 
cancer.
Introduction
Prostate cancer, the second leading cause of cancer death in men in the United States, exhibits a broad 
range of clinical and histological heterogeneity, and its diagnosis and prognosis depend substantially 
on tumor behavior at the molecular level. Microarray technology has helped to identify tumor subtypes, 
and to search for diagnostic and prognostic biomarkers (Magee et al. 2001; Welsh et al. 2001; Singh 
et al. 2002; Lapointe et al. 2004).
Individual microarray investigations typically involve few clinical samples, and therefore have low 
statistical power to identify predictive genes. The growing availability of public data sets facilitates 
combining data across studies and laboratories, which can increase the sample size and thus the power 
to detect true expression results with fewer false positives. Such meta-analyses are critically important 
for the further development of this technology as a useful clinical tool.
Several investigators have performed meta-analysis on microarray data in cancer research (Rhodes 
et al. 2002 and 2004; Ghosh et al. 2003; Choi et al. 2004; Wang et al. 2004); however, signiﬁ  cant analytical 
challenges to this process remain. They include a lack of accepted data standardization procedures; 
substantial experimental variability; incomparable numerical scales of expression measurements across 
platforms; and the need for associated clinical and pathological information for each microarray data 
set, which is not always available.
We developed a novel approach for combining tumor gene expression measurements across microarray 
platforms, and evaluated its usefulness for biomarker discovery. Our objectives were to correlate gene 88
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expression measurements with prognostic indices, 
and to construct probabilistic models in order to 
reveal genes that signiﬁ  cantly separated patients 
with good prognoses from patients with poor 
prognoses.
Feature selection is a critical step for building 
models to predict outcomes or classify samples 
based on high dimensional data, such as microarray 
gene expression measurements. The goal is to 
select a subset of features that is optimal for 
classiﬁ  cation or prediction. Although it is reasonable 
to believe that a small set of genes contains enough 
information to distinguish clinically relevant 
categories, the practical question of how best to 
select an informative set of features from large-
scale expression data remains open.
A wide variety of feature selection algorithms 
have been proposed (Guyon and Elisseeff, 2003; 
Pochet et al. 2004; Inza et al. 2004; Hauskrecht et al. 
2005; Choudhary et al. 2006). The algorithms 
include ‘filters’ that select features based on 
univariate rankings (Golub et al. 1999; Chow et al. 
2001; Dudoit et al. 2003), data reduction methods 
such as principal component analysis (West et al. 
2001; Tan et al. 2005); and ‘wrappers’ like genetic 
algorithms (Ooi et al. 2003; Deutsch 2003; Baggerly, 
et al. 2003) that attempt to select multiple features 
simultaneously based on their performance on a 
training set. Although the results are encouraging, 
there is still no convincing evidence to show that 
any particular algorithm always performs better.
The fundamental difﬁ  culty lies in the tendency 
to over-fit the data–to select features that are 
accidental artifacts of a single data set–when the 
number of features is far greater than the number 
of samples to be classiﬁ  ed. Consequently, any 
proposed method of feature selection and classiﬁ  -
cation must be validated either on a completely 
independent data set or by cross-validation 
(repeatedly splitting the initial data set into subsets 
for training and testing). For proper cross-
validation, feature selection must be performed 
separately during each iteration, only using 
information from the current training set. If, 
instead, one selects features using the entire data 
set and only cross-validates the step that optimizes 
the parameters in the classiﬁ  er, then one gets an 
overly optimistic estimate of the classiﬁ  cation 
accuracy (Ambroise and Maclachlan, 2003; Simon 
et al. 2003B).
In this study, we applied several algorithms for 
feature selection to a combined prostate cancer 
array data set. The performance of all algorithms 
was evaluated using leave-one-out cross-validation, 
with the feature selection step performed inside the 
cross-validation loop. In particular, we introduced 
a new approach, greedy robust feature selection 
(GRFS), and applied it to the combined data. GRFS 
is a wrapper method for feature selection that relies 
on another leave-one-out loop (inside the cross-
validation loop) to identify a robust feature set. The 
usefulness of GRFS, as well as the issues involved 
in feature selection and cross-validation, will be 
discussed.
Materials and methods
We used two publicly available microarray gene 
expression data sets, which we refer to as the 
Harvard and the Stanford data set. These data were 
collected using two distinct platforms: Affyme-trix 
GeneChip
® U95A and two-color ﬂ  orescent-labeled 
glass microarrays (Table 1).
The Harvard data set was obtained through a study 
of the correlation of gene expression and clinical 
behavior for prostate cancer (Singh et al. 2002). 
Table 1. Sources of Microarray Data Sets for Meta-Analysis.
Institution Results 
Published
Author
Array 
Type
Number of 
Probe Sets/
Clones
Healthy 
Samples
Tumor 
Samples
Harvard Cancer 
Cell 
(2002)
Singh et al. Affymetrix 
U95-Av2
12625 50 52
Stanford PNAS 
(2004)
Lapointe et al. Two-color 
glass cDNA
42129 41 71*
*Stanford tumor samples include 9 lymph node metastases.89
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The data include 102 Affymetrix U95Av2 GeneChips 
from 50 healthy prostate samples and 52 prostate 
tumor samples, consisting of 12,625 probe sets 
representing 7,865 distinct UniGene clusters 
(UniGene Build 170). It is available at the Center 
for Genome Research, Whitehead Institute (http://
www.broad.mit.edu/cgi-bin/cancer/datas-ets.cgi).
The Stanford, two-color fluorescent cDNA 
microarray data were obtained through a study 
identifying clinically relevant subtypes of prostate 
cancer (Lapointe et al. 2004). The set consists of 
data from 41 healthy prostate specimens, 62 pri-
mary prostate tumors, and 9 unmatched lymph 
node metastases. The microarrays contain 42,129 
spots for 38,804 different cDNA clones represent-
ing 21,287 distinct UniGene clusters (UniGene 
Build 170). The prostate cancer samples were 
labeled with Cy5. A common reference material, 
pooled from 11 established human cell lines, was 
labeled with Cy3. The raw micro-array data can 
be downloaded from the Stanford Microarray 
Database (http://cmgm.stanford. edu/pbrown/).
Prostate cancer prognostic indices
Prostate tumor prognosis is indicated by the 
Gleason score, ranging from 2 to 10, which is based 
on the architectural pattern of the prostate tumor, 
and indicates its aggressiveness (Gleason and 
Mellinger, 1974; Gleason, 1977). Clinical studies 
have shown that the Gleason score correlates with 
tumor prognosis: a Gleason score of 6 or lower is 
associated with stable disease and a good outcome; 
8 or higher is associated with a bad outcome and 
the need for additional treatment; and a score of 7 
is associated with extremely variable tumor 
behavior. Determining the molecular signature 
associated with each Gleason score and predicting 
the clinical course of prostate cancer remains an 
important research challenge.
Gleason scores ranging from 5 to 9 are available 
for tumor samples in both Stanford and Harvard 
data sets. To make the investigation clinically 
relevant, we divided the Gleason scores into three 
categories: low (6 or lower), medium (7; 3+4 and 
4+3), and high (8 or higher). The patient popula-
tions with tumors categorized into the three groups 
are summarized in Table 2.
Processing and combining data
For the Affymetrix GeneChip data, we used DNA-
Chip Analyzer (dChip), version 1.3 (Li and Wong, 
2001), to obtain gene expression values based on 
a model that only used perfect match (PM) features. 
We used dChip to normalize to the array with 
median brightness, and rescaled the normalized 
data so that the 75
th percentile equaled 1000.
We performed intensity-dependent loess 
normalization on each cDNA microarray in order 
to remove intensity-dependent dye bias (Dudoit 
et al. 2002; Yang et al. 2002), and then normalized 
the background-corrected spot intensities of each 
channel so that the 75
th percentile equaled 1000. 
We log transformed (base 2) both array data sets 
for further analysis.
We used the following standardization proce-
dure for each gene expression level based on the 
mean expression measurements of, and the stan-
dard deviation estimated from, the arrays of healthy 
prostate tissue:
  giS
i S i healthy
i healthy
,
,,
,
XX
=
− ()
() V  (2.1)
Here gi, S denotes the standardized expression 
measurements of gene i in sample S; Xi, S is the (log 
transformed) expression level of gene i in sample S 
before being standardized; Xi, (healthy) is the mean 
expression of gene i across all healthy prostate 
Table 2. Summary of the Gleason Grades of Both Microarray Data Sets.
Gleason Grade
Institution Low (L) 
2+3, 3+2, 3+3
Medium (M) 
3+4, 4+3
High (H) 
4+4, 4+5
NA Total
Harvard 
(52 prostate cancer patients) 19 29 4 0 52
Stanford 
(62 prostate cancer patients) 24 22 15 1 62
Total Patient Population 43 51 19 1 11490
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samples; and vi, (healthy) is the standard deviation (SD) 
of gene i computed across all arrays of healthy 
prostate samples. On each platform, standardized 
expression measurements from healthy prostate 
samples should be normally distributed with mean 
= 0 and SD = 1.
After standardization, the transcripts that have 
multiple clones on a two-color glass array or mul-
tiple probe sets on an Affymetrix array for the same 
gene need to be combined. We combined these 
measurements by averaging. Since averaging 
changes the standard deviation slightly, we 
re-standardized each data set. This process simply 
adjusted by the square root of the number of clones 
or probe sets.
We applied UniGene matching for the critical 
step of determining which genes had been included 
on all platforms. For each platform, we assumed 
that the array manufacturer’s GenBank accession 
numbers were accurate. Because GenBank 
numbers identify sequences rather than genes, we 
replaced them with identiﬁ  ers linked to the concept 
of an individual gene: UniGene cluster identiﬁ  ers. 
To update the gene annotations to a recent UniGene 
build (Build 170, July 2004), we used in-house 
software, GeneLink, which is freely available 
online (http://bioinformatics. mdanderson.org/
GeneLink/). We then combined the array data from 
genes that were common to both platforms, and 
obtained a data set consisting of the standardized 
measurements of 6402 genes from 114 patients 
with prostate cancer.
Classiﬁ  cation models were constructed using 
the implementations of logistic regression and 
linear discriminant analysis (LDA) in S-PLUS
® 
(Insightful Corp., Seattle, WA).
Feature selection
Technically, performing LDA requires computing 
and inverting the covariance matrix, which requires 
the number of genes used for prediction to be less 
than the number of samples used for the investigation. 
Feature selection is thus the critical step when 
applying LDA to microarray data sets. We explored 
several algorithms for feature selection.
A greedy algorithm is a common method for 
ﬁ  nding an approximate optimal solution to a prob-
lem. The algorithm extends a small part of the data 
structure by adding locally optimal components 
one by one, until it achieves an optimal global 
solution. Forward stepwise selection in logistic 
regression is an example of a greedy algorithm.
We considered a set of genes to be optimal if it 
maximized the Mahalanobis distance between the 
two groups. To perform the greedy algorithm, we 
started with the gene that had the lowest p-value for 
a two-sample t-test. We then added one gene at time 
to minimize the Mahalanobis distance, and 
computed the classiﬁ  cation error from the LDA. 
This selection process stopped when a perfect 
classiﬁ  cation result was reached or when the process 
stopped improving the classiﬁ  cation error.
A genetic algorithm (GA) is a heuristic search 
process based on natural genetic selection. Brieﬂ  y, 
a string (as an individual) containing encoded 
parameters (attributes) of the solution is used to 
represent each potential solution. A set of strings 
forms a population, and a pool of random strings 
initializes the population. A ﬁ  tness function (here, 
the Mahalanobis distance) determines the degree of 
ﬁ  tness of each string. Genetic operators (reproduction, 
crossover and mutation) are applied to the strings 
in the pool, creating a new population of strings for 
the next generation. This process is repeated until a 
termination condition, such as a maximum number 
of generations to be run, is satisﬁ  ed.
Principal components analysis (PCA) attempts 
to ﬁ  nd a set of orthogonal principal components to 
preserve as much variance as possible in independent 
variables. This algorithm projects the observations 
(specimen) from a high-dimensional variable space 
(gene expression) to a low-dimensional subspace, 
so that the prediction is feasible. PCA feature 
selection uses principal components instead of 
individual genes to perform classiﬁ  cation and 
prediction, selecting the first few principal 
components, which explain the most variance 
(Khan et al, 2001; West et al. 2001).
We introduce a greedy robust feature selection 
(GRFS) approach built on the Leave-one-out cross 
validation (LOOCV) procedure to keep the most 
frequently identified features for building a 
predictive model. Leaving out one sample at a time, 
we used a greedy-LDA to identify a set of predictive 
genes. We counted the number of times a gene was 
selected, and retained only the most frequently 
identiﬁ  ed genes as the selected features.
Results
The assumption of our standardization procedure is 
that the expression proﬁ  les from healthy prostate 
should be distributed similarly across array 
platforms, with the differences in the means and 
standard deviations resulting from differences in 91
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array technology. To validate this assumption, we 
applied a two-sample Kolmogorov-Smirnov (KS) 
goodness-of-ﬁ  t test to the re-standardized healthy 
population expression proﬁ  les on a gene-by-gene 
basis. The null hypothesis of the KS test is that the 
expression distributions of each gene from healthy 
prostate tissues on both platforms have identical 
cumulative distributions. To adjust for multiple 
testing, the resulting p-values were analyzed using 
a beta-uniform mixture (BUM) model (Pounds and 
Morris, 2003). Under the null hypothesis, we 
expected to see a uniform distribution of the resulting 
p-values from the KS test. The p-value distribution 
is plotted in Figure 1. The plot indicates that the 
p-values were distributed nearly uniformly, with a 
small population (about 7%) satisfying p  0.05. 
Therefore, the assumption for standardizing gene 
expression proﬁ  les appears to be statistically valid.
We built a logistic regression model to predict 
Gleason score (low or high) in two steps: (i) 
identiﬁ  cation of candidate genes and (ii) forward 
stepwise variable selection. We fit the logistic 
regression model in S-PLUS
® gene-by-gene, and 
computed the regression p-value for each gene. We 
found the study effect in the model to be statistically 
insigniﬁ  cant. Adjusting for multiple testing, we applied 
BUM to model the resulting p-values, and assessed 
the false discovery rate (FDR) to identify signiﬁ  cant 
genes (Benjamini et al. 1995) (see Figure 2).
To build an effective model, we applied forward 
stepwise variable selection to ﬁ  nd an optimal set 
of predictive genes from the top 20 genes (sorted 
by p-values) identified by logistic regression, 
adding genes to the model one at time. Using 
S-PLUS
®, we selected a gene at each stage based 
on the value determined by the likelihood function 
of the model. From the top 20 genes, we found a 
7-gene predictive model that provided perfect 
classiﬁ  cation for our combined data set. These 
seven genes are LTBP2, TIMP2, CDH11, RAP140, 
CXCR4, ProSAPiP2, and SEPT6.
Since we did not have an independent testing 
set that contained low and high Gleason scores, we 
applied the 7-gene model to a data set that contained 
data from prostate tissue given a Gleason score of 
7, and which was part of the combined data with 
the expression measurements from 6402 genes and 
52 patients. The model separated them into good 
or poor prognostic categories that were associated 
with Gleason grades 3+4 or 4+3, respectively 
(Fisher exact test; p = 0.033). Figure 3 illustrates 
the ﬁ  ndings.
We performed LOOCV to validate our logistic 
regression model. To properly validate the model, 
the selection of top genes and forward stepwise 
variable selection were built into each LOOCV 
(Simon, 2003B). The misclassiﬁ  cation rate by 
LOOCV was 31%. Of 43 tumors with low Gleason 
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Figure 1. Distribution of p-value computed from Komogorov-Smirnov (KS) goodness-of-ﬁ  t test to the expression proﬁ  les from healthy prostate 
samples re-standardized on a gene-by-gene basis. The plot illustrates the p-values distributed near uniformly. The superimposed curves 
represent the division into uniform and β contributions.92
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Figure 2. Analysis of p-values as a beta-uniform mixture. Left: Histogram of the p-values from a chi-squared test of the quality of the ﬁ  t 
when adding a single gene to the logistic model. Right: The plot describing the relationship between FDR and single-test p-values.
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scores 4+3. The results are statistically signiﬁ  cant with p=0.033 (Fisher's exact test).
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scores and 19 with high scores, the model correctly 
predicted 33 and 10, respectively. The number of 
predictors selected varied (from 4–9 genes), and 
predictors were inconsistent across each leave-one-
out training set.
Because the cross-validated misclassiﬁ  cation 
rate was higher than we expected (31%), we 
evaluated other methods for building classiﬁ  ers 
from this data set. We built a prediction model from 
a larger set of candidate genes identiﬁ  ed by logistic 
regression, ﬁ  rst identifying 231 genes based on 
FDR = 5% (p  0.0032), and then applying a 
forward stepwise variable selection procedure. We 
found a 4-gene model that provided perfect 
classiﬁ  cation for our combined data set: LTBP2, 
JAG1, ASTN and PORIMIN. The misclassiﬁ  cation 
rate by LOOCV was 26%. Again, the number of 
predictors selected varied (from 3–5 genes), and 
genes selected as predictors were inconsistent 
across each leave-one-out training set.
To build the LDA model, we ﬁ  rst selected a 
subset of candidate genes based on a univariate 
two-sample t-test between the groups with low and 
high Gleason scores. We computed the p-value of 
each gene according to the test statistic, and then 
used BUM to adjust for multiple testing. To identify 
signiﬁ  cant differentially expressed genes between 
the two groups, we set FDR = 10%. With this 
criterion, the subset contained about 200–300 
genes, depending on the leave-one-out training set. 
Table 3 summarizes the results of the cross-
validation for each model we tested.
From the selected subset of candidate genes, we 
searched for a small set of genes that achieved the 
best discrimination by the greedy algorithm. In 
order to correctly validate the model, we built the 
selection of candidate genes and feature selection 
into the LOOCV, i.e., for each leave-one-out 
training set, we repeated the two-sample t-test and 
greedy feature selection. The gene with the smallest 
p-value from the t-test was chosen as the ﬁ  rst gene 
for the model. From each training set, the greedy 
algorithm selected about 10–20 features that 
achieved perfect classification. However, the 
LOOCV misclassiﬁ  cation rate was 31%, and the 
features selected from each leave-one-out training 
set were inconsistent.
We next applied GA to search for the optimal 
set of 10 features that gave the best separation of 
the two Gleason groups (low and high). For each 
feature N (N = 1,2, ... 10), we performed GA using 
different randomly generated initial populations, 
each containing 200 sets of N genes. The GA was 
allowed to evolve for 500 generations; each run of 
the GA converged. We chose the set of N genes 
with maximum ﬁ  tness as the selected features to 
perform LDA. For LOOCV, we ran the GA on each 
leave-one-out training set to identify the 10 “best” 
genes, and then performed the LDA. The LOOCV 
misclassification rate was 28%. The model 
performed poorly in predicting patients with high 
Gleason scores, and genes selected as features from 
each leave-one-out training set were inconsistent.
We performed PCA on the selected candidate 
genes. Keeping enough components to explain 
80% of the variance, we then used these components 
as predictors to perform the LDA. To explain 80% 
of the variance, thePCA-LDAmodel selected 
about 10–20 components and achieved perfect 
classiﬁ  cation on the training sets. The LOOCV 
misclassiﬁ  cation error was 24%.
We applied the GRFS-LDA approach. In this 
two-level LOOCV feature selection process, we 
retained the most frequently identiﬁ  ed genes from 
the second level. More precisely, after leaving one 
sample out, we applied GRFS using another level 
of leave-one-out on the training set. We retained 
features that were selected more than 20 times (out 
of 60) in the second level leave-one-out, and used 
those features to train an LDA model and to predict 
Table 3. LOOCV Results of the Prediction Models.
Model
Features 
Selected
LOOCV Misclassiﬁ  cation 
Rate (%)
Logistic Regression - Forward Stepwise 4 – 9 31
Greedy - LDA 10 – 20 31
Genetic algorithm - LDA 10 28
PCA - LDA 10 – 20 24
Robust feature selection - LDA 5 – 11 3194
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the status of the left-out sample at the ﬁ  rst level. 
The model selected 5–11 features, and the LOOCV 
misclassiﬁ  cation rate was 31%.
Simulation and permutation studies
The LOOCV results suggested that all 5 methods 
overﬁ  t the training set. To understand this problem, 
we performed a simulation study and two 
permutation studies. We ﬁ  rst simulated 20 data sets 
containing 6200 variables (genes) and two groups, 
with 40 and 20 randomly selected samples on each 
group. The data sets were similar to our training 
set in dimensions (variable number and sample 
size), and were simulated as independent, identi-
cally distributed, with standard normal noise. We 
applied a greedy algorithm for feature selection, 
followed by LDA. In each simulation, between 
8 and 11 genes were enough to achieve perfect 
classiﬁ  cation, even though there was no class 
structure.
We then performed two permutation studies 
using the combined prostate cancer data set. In the 
ﬁ  rst, we permuted the sample labels 50 times, 
selecting the top 200 genes by a two-sample t-test, 
followed by the greedy-LDA. The model achieved 
perfect classiﬁ  cation on the training set with about 
20 genes (11–27 on all 50 permutations). In the 
second, we permuted the sample labels 10 times 
and used all 6204 genes with greedy-LDA. With 
the selection of about 13 genes on average (range 
9–15), the model achieved perfect classiﬁ  cation 
on the training set.
The results suggested that these models overﬁ  t 
the training data by selecting too many features. 
We then tested using fewer features ( 8) to build 
the LDA model (see Table 4). Unexpectedly, the 
performance of three of the feature selection 
methods (Greedy, GA, and PCA) showed no 
signiﬁ  cant improvement. However, using only two 
features, the GRFS-LDAmodel achieved the best 
classiﬁ  cation results with a LOOCV misclassiﬁ  cation 
rate of 15%. The two genes selected by GRFS-LDA 
on the full data set are latent transforming growth 
factor beta binding protein 2 (LTBP2; Hs.512776) 
and pro-oncosis receptor inducing membrane 
injury gene (PORIMIN; Hs.503709). These two 
genes were included in the 4-gene logistic 
regression model.
Finally, we wanted to test whether an overall 
LOOCV accuracy of 15% was likely to be better 
than chance on a data set of this size. To test this, 
we applied the GRFS-LDA algorithm to multiple 
(n=10) simulated non-informative data sets with 
the same dimensions as the combined prostate 
cancer data set. Each simulation generated inde-
pendent, identically distributed measurements. The 
random data sets were normally distributed with 
the same mean and standard deviation as the com-
bined prostate cancer data. We repeated the full 
analysis selecting fewer than 8 features. The results 
showed that misclassiﬁ  cation rates on random data 
sets were much higher, typically on the order of 
40% or more (Figure 4), which is consistent with 
the fact that these data sets actually have no class 
structure. One should also note that LOOCV mis-
classiﬁ  cation rates of 30% appear not to be unlikely 
with 5 or more features.
Discussion
We have introduced a standardization procedure 
to combine cancer array data across institutions. 
Using the Kolmogorov-Smirnov test, we conﬁ  rmed 
Table 4. Results of Fitting the Model with Fewer Features.
Misclassiﬁ  cation Rates of Cross-validation
Number of Features Greedy-LDA 
(%)
GA-LDA 
(%)
PCA-LDA 
(%)
Robust Selection-LDA 
(%)
13 3 3 2 2 7 1 9
22 4 2 6 2 7 1 5
33 1 1 9 2 3 2 1
42 6 2 4 2 2 2 4
52 9 2 1 1 9 2 9
62 9 3 1 1 9 2 9
72 6 2 4 1 9 3 195
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that the distributions of gene expression from 
healthy prostate tissue were essentially the same 
after this procedure, allowing us to combine the 
prostate cancer data.
We have also examined whether the combined 
data can be used to identify clinical relevant prog-
nostic markers for prostate cancer. We chose to 
apply two widely used statistical approaches, since 
we believe most classiﬁ  cation methods should per-
form similarly once the appropriate predictive genes 
have been selected. The comparative study by 
Dudoit and Fridlyand (2003) supports this idea.
We did not intend to compare prediction 
methods to determine which one performed better. 
Instead, we focused primarily on combining 
expression data and on feature selection.
Feature selection appears to be a major challenge 
in building an accurate predictive model, and is 
complicated by large expression data sets with 
substantial measurement noise. No one has yet 
reported convincing results with proper validation. 
Michiels and colleagues recently re-analyzed seven 
published microarray cancer data sets, observing 
that prediction models based on (containing about 
50 genes) predicting cancer prognosis were highly 
unstable and in their analysis depended strongly on 
the selection of patients in the training set (Michiels 
et al. 2005). Our simulation and permutation 
studies show that it is possible to achieve “perfect” 
classifications on a training set using a small 
number of “noise” genes, as few as 10 to 20. These 
results suggest that overﬁ  tting by selecting too 
many features remains a major problem for the 
types of models we have studied, and that an 
independent validation test set is required.
Although the accuracy of a predictive model 
may appear excellent when it is tested on the same 
data set from which it was derived, it may perform 
poorly when applied to a new data set. This is the 
well-known overﬁ  tting problem, which occurs 
when too many parameters are ﬁ  t to a small num-
ber of data points, resulting in parameters being ﬁ  t 
to random noise (Simon et al. 2003 A, 2003B). 
Michiels and colleagues also observed that the 
misclassiﬁ  cation rate estimated by cross-validation 
was typically much larger than the misclassiﬁ  cation 
rates that had been reported in the original papers 
without cross-validation (Michiels et al. 2005).
LOOCV is commonly used for validating a 
method to build predictive models. Since feature 
selection is an important part of model development, 
to properly validate a model, the feature selection 
process must be built into the LOOCV. That is, for 
each leave-one-out training set, we must repeat the 
feature selection process; otherwise, we would 
obtain a biased estimate of the accuracy of the 
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Figure 4. Misclassiﬁ  cation rates of leave-one-out cross validation obtained by performing robust feature selection approach on randomly 
generated data sets (n=10). For seven selected features, the median values range from 41.85 to 48.40.96
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model (Ambroise and Maclachlan, 2003; Simon 
et al. 2003B). When applying LOOCV to the 
combined prostate cancer data set, we found that 
(1) the LOOCV misclassiﬁ  cation rates were on the 
order of 25–30%, and (2) the selected features 
varied from one training set to another and 
depended strongly on which samples were used 
for training.
We hypothesized that the instability in feature 
selection might be responsible for the high misclas-
siﬁ  cation rate. To avoid this problem and select 
more consistent features, we developed the GRFS 
algorithm. This approach attempts to use leave-one-
out methods to select a set of genes that should be 
more stable. The robust approach, however, did not 
immediately improve the mis-classiﬁ  cation rate as 
we expected. In our ﬁ  rst application of the method, 
using a criterion that retained all features that were 
found in one third of the individual models, we 
selected between 5 and 11 features. Since our 
simulations suggested that we could ﬁ  nd between 
8 and 11 features to classify the samples by chance, 
we hypothesized further that better results would 
be obtained by restricting the number of selected 
features. No improvement in LOOCV misclassiﬁ  -
cation rates was observed with most of the feature 
selection methods we examined. However, GRFS 
with only two features provided the best results, 
with a LOOCV misclassiﬁ  cation rate of 15%. Based 
on additional simulations, we concluded that this 
rate was better than would be expected on random 
data without a real class structure.
We conclude that predictive models based on 
most current microarray data sets may have to 
severely limit the number of selected features in 
order to build models that will cross-validate and 
thus have a greater likelihood of generalizing to 
future data sets. Our results suggest that studies 
with 60 samples cannot use 10 features; Michiels’ 
results suggest that studies with 200 samples 
cannot use 50 features. How to determine the 
number of features that can be incorporated in a 
predictive model, as a function of the sample size, 
remains an open question.
The best LOOCV misclassification rate we 
achieved on the combined prostate cancer data set 
was only 15%. In addition to the small sample size 
(62 tumor samples), this data set is challenging for 
two reasons. First, because it combines data from 
two studies at different institutions using different 
microarray platforms, we expect the data to be more 
variable than data from a single study. Second, we 
tried to ﬁ  nd a molecular predictor to distinguish 
low-from high-Gleason-score prostate cancer. Our 
models predicted the patients with low Gleason 
scores reasonably well, but performed poorly when 
identifying patients with high Gleason scores. The 
imbalance of the two patient population groups 
could contribute to the problem. However, we 
expect the molecular differences between these 
tumors to be subtler and signiﬁ  cantly harder to 
detect than the molecular differences between 
prostate cancer and healthy prostate.
The results from this investigation suggest that 
we are still far from having a deﬁ  nitive method for 
feature selection. Greedy robust feature selection 
appears promising when linked to a strategy that 
limits the number of features. Due to the limited 
size of the combined data set, and the lack of 
validation through independent testing, we make 
no attempt to interpret the biological signiﬁ  cance 
of the predictive genes identiﬁ  ed during model 
development. Selecting a set of “best” predictors 
and building a predictive model that avoids overn-
tting gene expression data remains a signiﬁ  cant 
challenge.
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